Terms: = Lymphoma AND CARS, P49589, 833, ENSG00000110619 AND Treatment
161 results:
1. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
[TBL] [Abstract] [Full Text] [Related]
2. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T; Matsuno Y; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Tsukasaki K; Tobinai K; Nagai H
Hematol Oncol; 2024 May; 42(3):e3272. PubMed ID: 38595316
[TBL] [Abstract] [Full Text] [Related]
3. Prediction model of radiotherapy outcome for Ocular Adnexal lymphoma using informative features selected by chemometric algorithms.
Zhou M; Wang J; Shi J; Zhai G; Zhou X; Ye L; Li L; Hu M; Zhou Y
Comput Biol Med; 2024 Mar; 170():108067. PubMed ID: 38301513
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Value of
Luo Y; Huang Z; Gao Z; Wang B; Zhang Y; Bai Y; Wu Q; Wang M
Korean J Radiol; 2024 Feb; 25(2):189-198. PubMed ID: 38288898
[TBL] [Abstract] [Full Text] [Related]
5. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.
Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR
Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118
[TBL] [Abstract] [Full Text] [Related]
6. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.
Sharma S; Sauer T; Omer BA; Shum T; Rollins LA; Rooney CM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958791
[TBL] [Abstract] [Full Text] [Related]
7. Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).
Kausar MA; Anwar S; El-Horany HE; Khan FH; Tyagi N; Najm MZ; Sadaf ; Eisa AA; Dhara C; Gantayat S
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37830150
[TBL] [Abstract] [Full Text] [Related]
8. Chimeric Antigen Receptor T Cells: Immunotherapy for the treatment of Leukemia, lymphoma, and Myeloma.
Rodríguez Gil de Montes AL; Spencer LM
Mol Cancer Ther; 2023 Nov; 22(11):1261-1269. PubMed ID: 37596239
[TBL] [Abstract] [Full Text] [Related]
9. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
Acharya L; Garg A; Rai M; Kshetri R; Grewal US; Dhakal P
J Investig Med; 2024 Jan; 72(1):32-46. PubMed ID: 37497999
[TBL] [Abstract] [Full Text] [Related]
10. treatment Selection and Survival in Patients with Gray Zone lymphoma: A Comprehensive Population-Based Analysis.
Samhouri Y; Jayakrishnan TT; Alnimer L; Bakalov V; Wegner RE; Khan C; Fazal S; Lister J
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):245-253. PubMed ID: 37023222
[TBL] [Abstract] [Full Text] [Related]
11. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
Moreno V; Vieito M; Sepulveda JM; Galvao V; Hernández-Guerrero T; Doger B; Saavedra O; Carlo-Stella C; Michot JM; Italiano A; Magagnoli M; Carpio C; Pinto A; Sarmiento R; Amoroso B; Aronchik I; Filvaroff E; Hanna B; Wei X; Nikolova Z; Braña I
Nat Commun; 2023 Mar; 14(1):1359. PubMed ID: 36914652
[TBL] [Abstract] [Full Text] [Related]
12. Co-opting signalling molecules enables logic-gated control of CAR T cells.
Tousley AM; Rotiroti MC; Labanieh L; Rysavy LW; Kim WJ; Lareau C; Sotillo E; Weber EW; Rietberg SP; Dalton GN; Yin Y; Klysz D; Xu P; de la Serna EL; Dunn AR; Satpathy AT; Mackall CL; Majzner RG
Nature; 2023 Mar; 615(7952):507-516. PubMed ID: 36890224
[TBL] [Abstract] [Full Text] [Related]
13. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract] [Full Text] [Related]
14. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or lymphoma, 1985-2010.
Larsen CM; Garcia Arango M; Dasari H; Arciniegas Calle M; Adjei E; Rico Mesa J; Scott CG; Thompson CA; Cerhan JR; Haddad TC; Goetz MP; Herrmann J; Villarraga HR
JAMA Netw Open; 2023 Feb; 6(2):e2254669. PubMed ID: 36735254
[TBL] [Abstract] [Full Text] [Related]
15. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.
Bove C; Arcangeli S; Falcone L; Camisa B; El Khoury R; Greco B; De Lucia A; Bergamini A; Bondanza A; Ciceri F; Bonini C; Casucci M
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593069
[TBL] [Abstract] [Full Text] [Related]
16. CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.
Vanegas YM; Mohty R; Gadd ME; Luo Y; Aljurf M; Qin H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):81-93. PubMed ID: 36537906
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Applications of Flow Cytometry in Cancer Immunotherapies: From Diagnosis to treatments.
Mishra HK
Methods Mol Biol; 2023; 2593():93-112. PubMed ID: 36513926
[TBL] [Abstract] [Full Text] [Related]
18. Next generations of CAR-T cells - new therapeutic opportunities in hematology?
Tomasik J; Jasiński M; Basak GW
Front Immunol; 2022; 13():1034707. PubMed ID: 36389658
[TBL] [Abstract] [Full Text] [Related]
19. Multispecific CAR T Cells Deprive lymphomas of Escape via Antigen Loss.
Furqan F; Shah NN
Annu Rev Med; 2023 Jan; 74():279-291. PubMed ID: 36332638
[TBL] [Abstract] [Full Text] [Related]
20. Diffuse Large B-Cell Epstein-Barr Virus-Positive Primary CNS lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics.
Pons-Escoda A; García-Ruíz A; Naval-Baudin P; Grussu F; Viveros M; Vidal N; Bruna J; Plans G; Cos M; Perez-Lopez R; Majós C
AJNR Am J Neuroradiol; 2022 Nov; 43(11):1567-1574. PubMed ID: 36202547
[TBL] [Abstract] [Full Text] [Related]
[Next]
